Medical Oncology Department, Institut Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif, France.
Hematol Oncol Clin North Am. 2011 Aug;25(4):813-33. doi: 10.1016/j.hoc.2011.04.006.
Vascular endothelial growth factor (VEGF) is, to date, the key element in the pathogenesis of renal cell carcinoma (RCC). VEGF pathway activation is responsible for the recruitment, migration, and expansion of endothelial cells, with this angiogenesis tumor model being characteristic of RCC. Different strategies have been developed for almost a decade to block the VEGF pathway in this setting. Four different compounds were approved for metastatic RCC (mRCC) in the past 6 years: bevacizumab, sunitinib, sorafenib, and pazopanib. Axitinib and tivozanib are also promising compounds under evaluation. The revolution in the management and prognosis of patients with mRCC is ongoing.
血管内皮生长因子（VEGF）是目前肾细胞癌（RCC）发病机制中的关键因素。VEGF 通路的激活负责招募、迁移和扩张内皮细胞，这种血管生成肿瘤模型是 RCC 的特征。近十年来，已经开发出了多种策略来阻断这种情况下的 VEGF 通路。在过去的 6 年中，有四种不同的化合物被批准用于转移性肾细胞癌（mRCC）：贝伐珠单抗、舒尼替尼、索拉非尼和帕唑帕尼。阿昔替尼和替沃扎尼也是正在评估中的有前途的化合物。mRCC 患者的管理和预后正在发生革命性的变化。
